Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

Sofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, Arianna Draghi, Marie Christine Wulff Westergaard, Signe Koggersbøl Skadborg, Nana Overgaard, Anders Bundgård Sørensen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Christina Westmose Yde, Thomas Trolle, Christian Garde, Jens Friis-Nielsen, Nis Nørgaard, Dennis Christensen, Jens Vindahl Kringelum, Marco Donia, Sine Reker Hadrup, Inge Marie Svane*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

79 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma'. Together they form a unique fingerprint.

Immunology and Microbiology